Video

Risk Assessment in Newly Diagnosed CLL

Related Videos
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Mazyar Shadman, MD, MPH
Ben Levy, MD, and Yan Leyfman, MD
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
David L. Porter, MD
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Carrie L. Kitko, MD
Lori A. Leslie, MD
Jean L. Koff, MD, MS
Related Content
Maurie Markman, MD
June 7th 2024

Oncologic Supportive Care Is Absolutely Critical—But How Do We Define It?

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Mark Frattini, MD, PhD
June 5th 2024

UCART22 Earns Orphan Drug Designation for Acute Lymphoblastic Leukemia in Europe

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Hematology - stock.adobe.com
June 3rd 2024

Decreased Azacitadine Dosing Shows Consistent Safety in Lower- and Intermediate-Risk MDS

DLBCL
June 2nd 2024

Tucidinostat Plus R-CHOP Improves EFS in DLBCL Expressing MYC and BCL2